Topiramate safely decreases body mass, hypertension. Topiramate reduces body weight and blood pressure with generally mild-to-moderate adverse effects, according to a randomized, placebo-controlled trial involving obese subjects with hypertension.
Topiramate safely decreases body mass, hypertension. Topiramate reduces body weight and blood pressure with generally mild-to-moderate adverse effects, according to a randomized, placebo-controlled trial involving obese subjects with hypertension.
The study, published in the American Journal of Cardiology, involved 531 individuals with established hypertension and body mass indices between 27 kg/m2 and 50 kg/m2 . Following a 4-week placebo run-in period, patients were randomly assigned to placebo or 1 of 2 doses of topiramate: 96 mg/d or 192 mg/d. Each subject received a standardized diet, exercise advice, and behavioral modification from run-in through study end.
The placebo and 96- and 192-mg groups had respective weight losses of 1.9% (±3.37%), 5.9% (±5.21%), and 6.5% (±4.85%) from baseline (P<.001 for each comparison with placebo) and decreases in diastolic blood pressure of 2.1 (±6.86%), 5.5 (±8.42%), and 6.3 (±7.70%) mmHg (P<.015 vs placebo). Systolic blood pressure was decreased by 8.6 (±12.26%) and 9.7 (±10.61%) mmHg in the 96- and 192-mg groups, respectively, and 4.9 (±11.32%) mmHg in the placebo group (P=NS).
Adverse events included paresthesia, fatigue, taste perversion, loss of appetite, and difficulty with concentration and attention. Initially scheduled for 60 weeks on medication, the sponsor ended the study early to develop a new controlled-release formulation. As a consequence, efficacy was assessed within a predefined modified intent-to-treat population-subjects who had enrolled early enough to potentially complete 28 weeks on medication.
Tonstad S, Tykarski A, Weissgarten J, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol. 2005;96:243–251.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More